Cost Control

Generic Substitution Policies That Work: Therapeutic Interchange, Step Therapy, and Quantity Limits Done Right

Why a 91% Generic Rate Doesn’t Always Mean You’re Maximizing Savings

Last spring, I sat with a 700-employee manufacturer’s HR director as he scrolled through his pharmacy claims dashboard. “We’ve got a 91.3% GDR. Our PBM says we’re best in class, so why are pharmacy costs still above $132 PMPM?” He’s not alone. Many mid-sized employers hit high generic rates but still see specialty drugs, costly combinations, or branded generics quietly eating up budget. The reality is, a high GDR only tells part of the story. If your plan lacks smart substitution guardrails, like well-designed step therapy, therapeutic interchange, and quantity limits, you’re leaving real money on the table and exposing your plan to surprise spend.

Getting these controls right means more than flipping a PBM toggle. Done wrong, you’ll drown in appeals and employee complaints. Done well, you’ll steer utilization to cost-effective drugs without creating unnecessary disruption.

Therapeutic Interchange: Moving Beyond “Generics Only”

Most PBMs substitute generics for exact ingredient matches, but true savings come when you look at therapeutic alternatives, different molecules with similar clinical effects. Think switching from Nexium to generic omeprazole, or from Lantus to Basaglar insulin. The difference adds up fast. For example, a large multi-site employer I advised recently identified 41 employees on brand-name Januvia at $595 per month despite metformin and several DPP-4 inhibitor generics available for $15-$60. By working with the PBM and their consultant, we mapped conversion options, engaged prescribers, and set a target conversion window of 90 days. Within 6 months, they saw a $112,000 annualized savings with minimal member disruption.

To do this well:

  • Request your PBM’s therapeutic interchange program drug list. Not all are equally comprehensive.
  • Run a disruption analysis first. Use your claims data (or a tool like RxPBM.ai) to see how many employees would be affected and what the alternatives cost.
  • Work with a pharmacy consultant or clinical pharmacist to review proposed switches for true clinical equivalence.
  • Allow for opt-outs or medical necessity exceptions, but require provider attestation, this avoids “rubber stamp” overrides.

Therapeutic interchange shouldn’t be a once-and-done project. Review annually, especially when new generics or biosimilars launch (like the recent adalimumab biosimilars for Humira). For drug pricing data and the latest launches, bookmark RxInfo.ai.

Step Therapy: Setting the Right Order Without Tripping Up Employees

Step therapy can be a double-edged sword. It works best for drug classes with clear clinical preference hierarchies, think GLP-1s for diabetes and weight loss, or rheumatoid arthritis biologics. For example, a 500-life white-collar employer recently grappled with $34,000/year Humira spend for several members. Upon adding step therapy, they required trials of biosimilars (Hadlima or Cyltezo, cost $18,000-$22,000/year) before authorizing Humira. Within four months, two-thirds of patients made the switch, netting an annualized savings of roughly $68,000 with no uptick in complaints or appeals.

The key is careful implementation:

  • Don’t apply step therapy as a blunt instrument. Limit to classes where generics or preferred brands are clinically accepted first-line options.
  • Use a phased rollout. Notify affected employees at least 60 days before go-live and provide clear communication templates to HR teams.
  • Monitor appeals monthly for the first two quarters, an uptick over 10% of step therapy cases means more clinical education or exception flexibility is needed.
  • Choose a PBM with real-time electronic prior authorization (ePA) to avoid lag times. Express Scripts, OptumRx, and CVS Caremark all offer ePA, but turnaround times and integration with provider e-prescribing systems vary.

Step therapy gets more scrutiny every year, make sure your policies are evidence-based and reviewed by a clinical pharmacy expert. For clinical positioning of drugs, I often reference ClinicalRx.ai for rapid, unbiased drug monographs.

Quantity Limits: Fighting Waste Without Creating Hassles

Every plan pays for pills or injectables that get tossed. Quantity limits can help, but blanket caps (“30 tablets per 30 days”) sometimes backfire, especially on drugs with variable dosing or off-label use. Here’s what works: set limits based on FDA-approved dosing and real-world claims data. When we reviewed GLP-1 claims for a logistics firm (300 employees), we found 8% of fills exceeded dosing guidelines, often from accidental early refills or dose escalation. By syncing quantity limits to clinical guidelines (Ozempic max 2 mg per week, Mounjaro max 15 mg per week), the plan cut waste by $24,000 in the first year with almost no member pushback.

Best practices for quantity limits:

  • Reference FDA labels and compendia, not just PBM defaults, especially for specialty and injectable drugs.
  • Audit for refill-too-soon patterns. Your PBM should provide this report quarterly.
  • Set up an exception process for unique cases (e.g., dose titration, split fill). Require clinical documentation to avoid abuse.
  • Revisit limits annually as guidelines evolve. Some PBMs lag in updating limits after label expansions.

What to Fix This Quarter: Audit Your Top Ten Drug Classes for Real Substitution Opportunity

Generic substitution policies shouldn’t run on autopilot. This quarter, pull your top ten drug classes by spend and claims volume. For each, map exactly which generics, therapeutic alternatives, and step edits are in place, and which aren’t. If you don’t have the bandwidth, ask your PBM or a pharmacy benefits consultant to run the analysis. The difference between “generics where possible” and “active, updated substitution and clinical controls” is almost always measurable, often $50,000-$100,000 on a mid-sized plan.

Get the data, ask tough questions, and set your next round of plan changes based on facts, not PBM marketing language. That’s how you build a pharmacy benefit that’s fair to employees, and your budget.